Identification of 8 Rare Deleterious Variants in ADAMTS13 by Next-generation Sequencing in a Chinese Population with Thrombotic Thrombocytopenic Purpura

Abstract

Objective

Thrombotic thrombocytopenic purpura (TTP) is a rare and fatal disease caused by a severe deficiency in the metalloprotease ADAMTS13 and is characterized by thrombotic microangiopathy. The present study aimed to investigate the genes and variants associated with TTP in a Chinese population.

Methods

Target sequencing was performed on 220 genes related to complements, coagulation factors, platelets, fibrinolytic, endothelial, inflammatory, and anticoagulation systems in 207 TTP patients and 574 controls. Subsequently, logistic regression analysis was carried out to identify the TTP-associated genes based on the counts of rare deleterious variants in the region of a certain gene. Moreover, the associations between common variants and TTP were also investigated.

Results

ADAMTS13 was the only TTP-associated gene (OR = 3.77; 95% CI: 1.82–7.81; P=3.6×10^ȡ4) containing rare deleterious variants in TTP patients. Among these 8 variants, 5 novel rare variants that might contribute to TTP were identified, including rs200594025, rs782492477, c.T1928G (p.I643S), c.3336_3361del (p.Q1114Afs*20), and c.3469_3470del (p.A1158Sfs*17). No common variants associated with TTP were identified under the stringent criteria of correction for multiple testing.

Conclusion

ADAMTS13 is the primary gene related to TTP. The genetic variants associated with the occurrence of TTP were slightly different between the Chinese and European populations.

Keywords

thrombotic thrombocytopenia purpura / ADAMTS13 / target sequencing

References

[1] SadlerJE. Pathophysiology of thrombotic thrombocytopenic purpura. Blood, 2017, 130(10): 1181-1188

[2] Kremer HovingaJA, GeorgeJN. Hereditary Thrombotic Thrombocytopenic Purpura. N Engl J Med, 2019, 381(17): 1653-1662

[3] MasiasC, CatalandSR. The role of ADAMTS13 testing in the diagnosis and management of thrombotic microangiopathies and thrombosis. Blood, 2018, 132(9): 903-910

[4] LottaLA, GaragiolaI, PallaR, et al.. ADAMTS13 mutations and polymorphisms in congenital thrombotic thrombocytopenic purpura. Hum Mutat, 2010, 31(1): 11-19

[5] Kremer HovingaJA, HeebSR, SkowronskaM, et al.. Pathophysiology of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. J Thromb Haemost, 2018, 16(4): 618-629

[6] van DorlandHA, TaleghaniMM, SakaiK, et al.. The International Hereditary Thrombotic Thrombocytopenic Purpura Registry: key findings at enrollment until 2017. Haematologica, 2019, 104(10): 2107-2115

[7] von KroghAS, Quist-PaulsenP, WaageA, et al.. High prevalence of hereditary thrombotic thrombocytopenic purpura in central Norway: from clinical observation to evidence. J Thromb Haemost, 2016, 14(1): 73-82

[8] de VriesPS, BoenderJ, SonneveldMA, et al.. Genetic variants in the ADAMTS13 and SUPT3H genes are associated with ADAMTS13 activity. Blood, 2015, 125(25): 3949-3955

[9] ManciniI, Ricano-PonceI, PappalardoE, et al.. Immunochip analysis identifies novel susceptibility loci in the human leukocyte antigen region for acquired thrombotic thrombocytopenic purpura. J Thromb Haemost, 2016, 14(12): 2356-2367

[10] JolyBS, CoppoP, VeyradierA. An update on pathogenesis and diagnosis of thrombotic thrombocytopenic purpura. Expert Rev Hematol, 2019, 12(6): 383-395

[11] ScullyM, CatalandS, CoppoP, et al.. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost, 2017, 15(2): 312-322

[12] PallaR, ValsecchiC, BajettaM, et al.. Evaluation of assay methods to measure plasma ADAMTS13 activity in thrombotic microangiopathies. Thromb Haemost, 2011, 105(2): 381-385

[13] ManciniI, ValsecchiC, LottaLA, et al.. FRETS-VWF73 rather than CBA assay reflects ADAMTS13 proteolytic activity in acquired thrombotic thrombocytopenic purpura patients. Thromb Haemost, 2014, 112(2): 297-303

[14] Kremer HovingaJA, MottiniM, LämmleB. Measurement of ADAMTS-13 activity in plasma by the FRETS-VWF73 assay: comparison with other assay methods. J Thromb Haemost, 2006, 4(5): 1146-1148

[15] ChenS, ZhouY, ChenY, et al.. fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics, 2018, 34(17): i884-i890

[16] McKennaA, HannaM, BanksE, et al.. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res, 2010, 20(9): 1297-1303

[17] LiH, DurbinR. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics, 2009, 25(14): 1754-1760

[18] DanecekP, BonfieldJK, LiddleJ, et al.. Twelve years of SAMtools and BCFtools. Gigascience, 2021, 10(2): giab008

[19] WangK, LiM, HakonarsonH. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res, 2010, 38(16): e164

[20] WangXJ, XuXQ, SunK, et al.. Association of Rare PTGIS Variants With Susceptibility and Pulmonary Vascular Response in Patients With Idiopathic Pulmonary Arterial Hypertension. JAMA Cardiol, 2020, 5(6): 677-684

[21] PovysilG, PetrovskiS, HostykJ, et al.. Rare-variant collapsing analyses for complex traits: guidelines and applications. Nat Rev Genet, 2019, 20(12): 747-759

[22] CamilleriRS, ScullyM, ThomasM, et al.. A phenotype-genotype correlation of ADAMTS13 mutations in congenital thrombotic thrombocytopenic purpura patients treated in the United Kingdom. J Thromb Haemost, 2012, 10(9): 1792-1801

[23] LevyGG, NicholsWC, LianEC, et al.. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature, 2001, 413(6855): 488-494

[24] LiuF, JinJ, DongNZ, et al.. Identification of two novel mutations in ADAMTS13 gene in a patient with hereditary thrombotic thrombocytopenic purpura. Zhonghua Xue Ye Xue Za Zhi (Chinese), 2005, 26(9): 521-524

[25] RankCU, Kremer HovingaJ, TaleghaniMM, et al.. Congenital thrombotic thrombocytopenic purpura caused by new compound heterozygous mutations of the ADAMTS13 gene. Eur J Haematol, 2014, 92(2): 168-171

[26] MatsumotoM, KokameK, SoejimaK, et al.. Molecular characterization of ADAMTS13 gene mutations in Japanese patients with Upshaw-Schulman syndrome. Blood, 2004, 103(4): 1305-1310

[27] PlaimauerB, FuhrmannJ, MohrG, et al.. Modulation of ADAMTS13 secretion and specific activity by a combination of common amino acid polymorphisms and a missense mutation. Blood, 2006, 107(1): 118-125

[28] MaQ, JacobiPM, EmmerBT, et al.. Genetic variants in ADAMTS13 as well as smoking are major determinants of plasma ADAMTS13 levels. Blood Adv, 2017, 1(15): 1037-1046

[29] KokameK, MatsumotoM, SoejimaK, et al.. Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity. Proc Natl Acad Sci USA, 2002, 99(18): 11902

[30] FidalgoT, MartinhoP, PintoCS, et al.. Combined study of ADAMTS13 and complement genes in the diagnosis of thrombotic microangiopathies using next-generation sequencing. Res Pract Thromb Haemost, 2017, 1(1): 69-80